Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate

Increasing evidence suggests that the peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily, plays an important role in physiological processes in the central nervous system (CNS) and is involved in cellular metabolism and repair. Cellular damage caused b...

Full description

Bibliographic Details
Main Authors: Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
PPARγ agonist
neurodegenerative disease
leriglitazone
neuroinflammation
mitochondria
clinical trials
Online Access:https://www.mdpi.com/1422-0067/24/4/3201

Internet

https://www.mdpi.com/1422-0067/24/4/3201

Similar Items